The Company
NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.
​
NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of oncological and immunological diseases.
NanoGhosts can be loaded with various drug types (i.e. small molecules, DNA, RNA, peptides, proteins), preserve MSC’s tropism to cancer cells, and selectively penetrate tumors (as demonstrated in various preclinical models of solid tumor, including brain tumors while crossing the BBB and pancreatic cancer), leading to a major reduction in tumor size and prolonged survival following a single treatment.
Management & Board of Directors
Prof. Marcelle Machluf
Founder (PhD)
-
Full professor and the former dean of the Faculty of Biotechnology and Food Engineering at the Technion - Israel Institute of Technology
​
-
President of the Israeli controlled release society
​
-
A member of the Council for Higher Education
​
-
Postdoc in drug delivery, gene therapy and tissue engineering in Harvard Medical School (USA)
Mr. Yonatan Malca
Co-Founder & CEO (MA)
-
Founder of DNA Biomedical Solutions (TASE:DNA), a life sciences holding company
​
-
BOD Member at Entera Bio, oral delivery of large molecules (NASDAQ:ENTX)
​
-
BOD Member at BeamMed, ultrasound devices for bone density assessment
​
-
Former CEO at Meitav Underwriting and Exec.
VP of Leumi & Co Underwriters
Dr. Osnat Bohana Kashtan
VP R&D (PhD, MBA)
-
15 years of pharma experience leading development of small molecule, peptide and cell-based therapies for immune disorders, cancer and neurodegenerative diseases,
from discovery to Phase 3 stage
​
-
Former Director of R&D at Cell Cure Neurosciences & Director of the Phase 3 Motixafortide project at BiolineRx
​
-
Postdoc in oncology, The Johns Hopkins SOM (USA)